Cleveland Clinic physician-researcher recognized as a Top Ten Clinical Research Achievement awardee by national organization of senior researchers and thought leaders from leading academic health centers.
Cleveland Clinic medical oncologist Nima Sharifi, MD, is a recipient of two of the six 2015 Challenge Awards presented by the Prostate Cancer Foundation. Dr. Sharifi’s research focuses on metabolic and molecular mechanisms of resistance to hormonal therapy in prostate cancer.
Cleveland Clinic made history in 2019 as the first hospital in the world to successfully perform a single-port robotic-assisted kidney transplant. Nearly two years later, the surgical team leading these efforts is reporting more successful outcomes and early experiences in kidney transplant and autotransplant.
Researchers at Cleveland Clinic are in search of the biological reason behind why men are more likely than women to develop COVID-19 and typically have more severe disease.
Homozygous inheritance of a common missense-encoding germline variation in HSD3B1 is associated with estrogen-driven postmenopausal breast cancer, according to a new study. This is the first-known mechanism that links germline inheritance to endogenous estrogen exposure and breast cancer.
Findings from a new study show that pharmacologically inhibiting the H6PD protein can reverse drug resistance in human-derived preclinical models of enzalutamide-resistant prostate cancer.
More than two out of three patients require no narcotics after surgery and are able to manage pain with only ibuprofen, acetaminophen or no pain medication at all.
Androgen-receptor (AR) antagonists can alter the metabolism of patients with prostate cancer, shows a recent study. And a transporter protein may become a new therapeutic target for kidney cancer.
An Italian-led study published earlier this year reported that androgen deprivation therapy may play a protective role against the risk of SARS-CoV-2 infection. Using an expansive enterprise-wide COVID-19 testing registry, Cleveland Clinic researchers set out to validate this report. Eric Klein, MD, discusses their findings.
A new test developed at Cleveland Clinic interrogates the HSD3B1 gene to determine if a prostate cancer patient has inherited the adrenal-permissive (1245C) or adrenal-restrictive (1245A) allele. The development of the test is an outgrowth of more than seven years of research at Cleveland Clinic.